Pelthos Therapeutics Inc.
PTHS
$25.11
-$0.03-0.12%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 273.47% | -5.59% | -196.93% | -- | -9.97% |
| Gross Profit | 941.83% | 5.59% | 196.93% | -- | 9.97% |
| SG&A Expenses | 296.50% | 24.54% | 30.72% | 49.25% | 77.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 208.10% | 0.79% | -5.20% | 10.34% | 129.28% |
| Operating Income | -131.16% | -0.79% | 5.20% | -10.34% | -129.28% |
| Income Before Tax | -138.84% | 7.72% | 18.00% | -7.79% | -118.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -134.22% | 7.72% | 18.00% | -7.79% | -118.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.22% | 7.72% | 18.00% | -7.79% | -118.92% |
| EBIT | -131.16% | -0.79% | 5.20% | -10.34% | -129.28% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 45.85% | 65.84% | 74.96% | 72.23% | 28.09% |
| Normalized Basic EPS | 45.37% | 65.84% | 74.96% | 72.23% | 28.09% |
| EPS Diluted | 45.85% | 65.84% | 74.96% | 72.23% | 28.09% |
| Normalized Diluted EPS | 45.37% | 65.84% | 74.96% | 72.23% | 28.09% |
| Average Basic Shares Outstanding | 169.27% | 81.01% | 173.15% | 336.45% | 333.05% |
| Average Diluted Shares Outstanding | 169.27% | 81.01% | 173.15% | 336.45% | 333.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |